Arkolith/Insider Trading/SNDX/Form 4

Metzger Michael A

Chief Executive Officer, DirectorSyndax Pharmaceuticals Inc (SNDX) · full profile →Form 4 · filed Mar 6, 2025
Net Selling
Open-Market Buys
$0
Open-Market Sells
$118K
Net Open-Market Flow
-$118K
Transactions
3
2 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Mar 4, 2025Sell(S)8K$15.05$118K300K
Mar 4, 2025Option exercise(M)8K$7.20$56K308K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Mar 4, 2025Option exercise(M)8K—$00

Transaction Codes

S
Open-market sale
M
Option exercise / conversion

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0000950170-25-034634) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML